Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 October 2021 | Story Lunga Luthuli and Vicky Simpson | Photo Supplied
Anton Engelbrecht _ Farmovs researcher
Anton Engelbrecht, FARMOVS Bioanalysis Specialist.

“At FARMOVS, we have the opportunity to work with the world’s top pharmaceutical companies, where we form part of the evaluation of labelled and/or conjugated antigens and antibodies that are developed for accurate quantification of endogenous and pharmaceutical compounds. Alternatively, commercially available kits and reagents are also used for the same purpose if the sponsor cannot supply the customised antigens/antibodies. The developed assay methods are put through a rigorous validation assessment to confirm the selectivity, sensitivity, and robustness of the assay,” says Anton Engelbrecht, FARMOVS Bioanalysis Specialist. 

FARMOVS, affiliated to the University of the Free State and operating from the Bloemfontein Campus, is a leading clinical research organisation (CRO) with a unique advantage. As the only on-site ISO15189-accredited and GLP-certified pharmacokinetic laboratory on the African continent, with numerous successful inspections by leading international regulators, it offers the highest quality bioanalytical services in a variety of biological matrices for the development of pharmaceutical products.

Engelbrecht says: “The team of bioanalytical experts thrives on the excitement generated by new discoveries that lead to better treatment of a variety of physiological diseases.”

Advanced technology backed by 47 years of bioanalytical experience

The clinical research organisation prides itself on advanced technology, backed by 47 years of bioanalytical experience. It has developed more than 580 validated analytical methods that adhere to the International Council for Harmonisation and the US Food and Drug Administration (FDA) guidelines. FARMOVS’ analytical methods have been used in more than 3 000 pre-clinical and clinical trials, contributing to the manufacturing of pharmaceutical drugs that are now used by households across the globe.

At FARMOVS, Engelbrecht says, it is a “world filled with novel methods of analysis and subsequent technological integration that expands the horizons of clinical research forming an important part of the discovery and production of new life-saving medicines that is constantly improving the quality of life of people all over the world”.

Engelbrecht says: “New technology and innovation should be the building blocks of any laboratory, and among these are the three fastest sample production members of our Immunochemistry Laboratory team – the STARLet pipettors.”

“We chose the Microlab® STARLet apparatus by Hamilton, because of its ability to perform sample analysis in large quantities at a greater speed by means of robotic pipetting and robotic automated microplate reading, which is a semi-automated process.”

He shared his excitement about improvements in the field of immunoassay development for the purposes of pharmaceutical analysis. This involves the preparation of unique immunoanalytical reagents, analysis of new categories of compounds, methodology, and instrumentation. The most important examples in this field are the continuous development of bead-based immunoassays.

Staying competitive in the industry

Immunoassay methods, such as radioimmunoassay (RIA) and enzyme immunoassay (EIA), among others, are also used at FARMOVS to analyse macromolecules for clients. “The RIA method is used for the determination of several pharmaceutically important compounds in biological fluids. RIA requires a sample containing the antigen of interest, a complementary antibody, and a radiolabelled version of the antigen. To increase the selectivity of an assay, all samples are pre-treated to eliminate high molecular weight endogenous matrix components, including anti-drug antibodies,” explains Engelbrecht.

Although FARMOVS has adequate technology to provide market-related results, the plan is to expand the team to include a multiplex platform that is a sensitive, fully automated immunoassay platform with multiplexing and custom assay capability. “This will pave the way to use an even more sensitive method to quantify biomarkers in the fields of oncology, neurology, cardiology, inflammation, and infectious disease. We aim to remain competitive in our industry, so naturally we must recruit the brightest and most evolved to join the team,” he says.

News Archive

UFS the only university in South Africa with a P-rated history researcher
2016-12-13

Description: Dr Daniel Spence  Tags: Dr Daniel Spence  

Dr Daniel Spence has been earmarked by the NRF
to become a future international leader in his field
of expertise.
Photo: Supplied

The University of the Free State (UFS) is the only university in South Africa with a P-rated History researcher. Dr Daniel Spence, a postdoctoral Research Fellow at the International Studies Group (IGS), and a member of the Vice-Chancellor’s Prestige Scholar’s Programme at the UFS, was last week awarded a National Research Foundation P-rating by the National Research Foundation (NRF). Dr Spence is the first South African historian to achieve this honour.

Leader of the pack
P-ratings are given to young researchers, usually under the age of 35, who have the potential to become leaders in their field. Researchers in this group are recognised by all, or the overwhelming majority of, reviewers as having demonstrated the potential to become future international leaders.

The rating is awarded on the basis of exceptional research performance and output from their doctoral and early postdoctoral research careers.

Other researchers from the UFS who obtained P-ratings in the past, are Prof Lodewyk Kock (1986), Prof Zakkie Pretorius (1989), and Prof Robert Schall (1991).

Extraordinary achievement lauded  
“It is an extraordinary achievement. There are fewer P-ratings, than there are A-ratings,” said Prof Neil Roos, associate professor at the ISG. Prof Roos said the P-rating was seldom awarded to researchers within the field of Humanities.

As a member of the ISG, Dr Spence’s research has flourished under the guidance of Prof Ian Phimister. Much of the success of this group is due to the way it operates as an incubator for high-level research, with scholars collaborating with each other.

In addition to Dr Spence’s magnificent P-rating, the ISG currently has three C1-rated researchers (established researchers with a sustained recent record of productivity in their field) and two Y1-rated researchers (researchers 40 years old or younger, who are recognised by all reviewers as having the potential to establish themselves as future leaders in their fields).

“From the time Dr Spence wrote his doctoral thesis on the colonial history of the Royal Navy, he has expanded his field of expertise so that he can address imperial and global histories of race,” said Prof Roos.

Demonstrated research excellence

Dr Spence secured a postdoctoral Research Fellowship at the UFS to develop an African case study to augment his Asian and Caribbean research thesis into a monograph. In March 2013, Dr Spence won a three-year NRF Postdoctoral Innovation Scholarship, and learned Kiswahili ahead of archival research in Kenya and Tanzania from April to May of that year. He has conducted archival and oral research in Singapore, Malaysia, Hong Kong, Australia, Kenya, Zanzibar, the Cayman Islands, Trinidad, and the UK.

Internationally renowned
Dr Spence is the author of two monographies, the Colonial Naval culture and British imperialism, 1922-67 and A History of the Royal Navy: Empire and Imperialism. He has been invited to present papers and chair panels at over 20 international conferences, workshops and seminars.

The NRF rating system is a benchmarking system through which individuals who exemplify the highest standards of research, as well as those demonstrating strong potential as researchers, are identified by an extensive network of South African and international peer reviewers.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept